Diagnosis: Cutaneous angiosarcoma of the scalp
A 72-year-old male presents with a bruise-like violaceous patch on the scalp that has persisted for six months without improvement. The lesion has gradually enlarged, prompting further evaluation for underlying causes, including neoplastic processes. Clinical examination reveals key features suggestive of a vascular tumor, necessitating a thorough diagnostic workup.
A 72-year-old male presents with a six-month history of a non-healing violaceous patch on the scalp. Initially described as a bruise, the lesion has enlarged and become more pronounced. The patient reports no associated pain or pruritus. On examination, the patch is noted to be irregularly shaped and has a firm consistency, with surrounding telangiectasia.Location: Scalp.Color: Violaceous with areas of erythema.Size: Approximately 4 cm in diameter.Surface: Irregular and partially ulcerated.Surrounding skin: Exhibits telangiectasia.
The lesion initially appeared as a small bruise after minor trauma to the scalp, with gradual enlargement noted over several months. The patient has a history of hypertension and is a former smoker with no significant family history of skin cancers. He denies any recent travel, exposure to chemicals, or other notable environmental factors. Prior treatments include topical steroids with no improvement.Onset: 6 months ago following minor trauma.Prior treatments: Topical steroids ineffective.Past medical history: Hypertension.Social history: Former smoker, quit 10 years ago.Family history: No known skin cancers.Environmental exposure: No recent travel or chemical exposure.
Acute / First-Line ManagementComplete surgical excision is the primary treatment for localized cutaneous angiosarcoma, aiming for clear margins.Adjuvant radiation therapy may be considered post-surgery, especially for high-risk lesions.Workup and Diagnostic ConfirmationHistopathological examination via biopsy is essential to confirm the diagnosis, revealing atypical vascular channels.Imaging studies, such as MRI or CT scans, may be utilized to assess for deeper invasion or metastatic disease.Long-Term ManagementRegular follow-up is necessary to monitor for recurrence, typically every 3-6 months for the first 2 years.Consideration for chemotherapy (e.g., taxanes) may be warranted in metastatic cases or unresectable disease.
Hemangioma: Often presents as a raised, bright red lesion, usually in younger patients, and typically involutes over time.Basal Cell Carcinoma: Usually presents as a pearly papule or ulcerated lesion, often with a history of sun exposure; biopsy shows nests of basaloid cells.Squamous Cell Carcinoma: Can present as an ulcerated, keratotic lesion; history of sun exposure is a key factor, and biopsy reveals atypical keratinocytes.Kaposi Sarcoma: Characterized by violaceous lesions, often associated with immunosuppression; may have a multifocal distribution.Melanoma: Can present as an irregular, pigmented lesion; key features include asymmetry, border irregularity, and color variegation.Pyogenic Granuloma: Typically presents as a rapidly growing red nodule, often following trauma; it bleeds easily and is more common in younger individuals.Dermatofibroma: Usually presents as a firm, tan-brown nodule with a characteristic dimple sign upon lateral compression.Chronic Inflammatory Dermatoses: Such as psoriasis or eczema, which may mimic vascular lesions but typically have associated scaling or itch.
High-Yield PearlsVascular lesions: Always consider angiosarcoma in persistent, non-healing violaceous lesions, especially on sun-exposed areas.Histopathology: Definitive diagnosis relies on biopsy, showing atypical vascular proliferation.Surgical excision: Complete excision with clear margins is the cornerstone of treatment for localized disease.Radiation therapy: May be beneficial as an adjunct to surgery, particularly in high-risk cases.Recurrence monitoring: Regular follow-up is crucial, as recurrence can occur even after initial successful treatment.Remember, early recognition and intervention are key in managing cutaneous angiosarcoma to improve patient outcomes.
Tags: angiosarcoma, tumors